Organon (OGN) Other Non-Current Assets (2020 - 2025)

Organon (OGN) posted Other Non-Current Assets of $390.0 million for Q4 2025, up 225.0% on a QoQ basis from $120.0 million in Q1 2021.

Analysis

Organon (OGN) Other Non-Current Assets (2020 - 2025) Analysis & Trends

Organon has reported Other Non-Current Assets for 3 years, with the latest figure at $390.0 million in Q4 2025.

On a quarterly basis, Other Non-Current Assets changed N/A year-over-year to $390.0 million in Q4 2025; TTM through Dec 2025 was $390.0 million, a N/A change from a year earlier, with the FY2025 full-year figure at $390.0 million, changed N/A from the prior year.
Other Non-Current Assets was $390.0 million for Q4 2025 at Organon, up from $120.0 million in the prior quarter.
The five-year high for Other Non-Current Assets was $390.0 million in Q4 2025, with the low at $120.0 million in Q1 2021.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Other Non-Current Assets (Qtr)
1	Johnson & Johnson	641.14 Bn	620.38 Bn	17.26 Bn	14.27 Bn
2	AbbVie	451.04 Bn	444.47 Bn	12.70 Bn	10.73 Bn
3	Merck	357.43 Bn	350.29 Bn	12.21 Bn	19.60 Bn
4	Novartis Ag	266.73 Bn	259.04 Bn	11.24 Bn	5.93 Bn
5	Pfizer	157.52 Bn	145.82 Bn	10.94 Bn	9.94 Bn
6	Sanofi	52.14 Bn	44.76 Bn	10.79 Bn	5.50 Bn
7	Revolution Medicines	42.88 Bn	42.88 Bn	-	42.45 Mn
8	Incyte	24.70 Bn	20.16 Bn	1.57 Bn	86.76 Mn
9	United Therapeutics	21.47 Bn	18.80 Bn	683.80 Mn	239.50 Mn
10	Organon	3.58 Bn	2.45 Bn	847.00 Mn	-

Historic Data

Download Data